Abstract
Single nucleotide polymorphisms (SNPs) are unique genetic differences between individuals that contribute in significant ways to the determination of human variation including physical characteristics like height and appearance as well as less obvious traits such as personality, behaviour and disease susceptibility. SNPs can also significantly influence responses to pharmacotherapy and whether drugs will produce adverse reactions. The development of new drugs can be made far cheaper and more rapid by selecting participants in drug trials based on their genetically determined response to drugs. Technology that can rapidly and inexpensively genotype thousands of samples for thousands of SNPs at a time is therefore in high demand. With the completion of the human genome project, about 12 million true SNPs have been identified to date. However, most have not yet been associated with disease susceptibility or drug response. Testing for the appropriate drug response SNPs in a patient requiring treatment would enable individualised therapy with the right drug and dose administered correctly the first time. Many pharmaceutical companies are also interested in identifying SNPs associated with polygenic traits so novel therapeutic targets can be discovered. This review focuses on technologies that can be used for genotyping known SNPs as well as for the discovery of novel SNPs associated with drug response.
Keywords: Diagnostics, pharmacogenomics, polymorphisms, pharmacotherapy, genotyping
Current Drug Discovery Technologies
Title: SNP Technologies for Drug Discovery: A Current Review
Volume: 5 Issue: 3
Author(s): Joanne Voisey and Charles Phillip Morris
Affiliation:
Keywords: Diagnostics, pharmacogenomics, polymorphisms, pharmacotherapy, genotyping
Abstract: Single nucleotide polymorphisms (SNPs) are unique genetic differences between individuals that contribute in significant ways to the determination of human variation including physical characteristics like height and appearance as well as less obvious traits such as personality, behaviour and disease susceptibility. SNPs can also significantly influence responses to pharmacotherapy and whether drugs will produce adverse reactions. The development of new drugs can be made far cheaper and more rapid by selecting participants in drug trials based on their genetically determined response to drugs. Technology that can rapidly and inexpensively genotype thousands of samples for thousands of SNPs at a time is therefore in high demand. With the completion of the human genome project, about 12 million true SNPs have been identified to date. However, most have not yet been associated with disease susceptibility or drug response. Testing for the appropriate drug response SNPs in a patient requiring treatment would enable individualised therapy with the right drug and dose administered correctly the first time. Many pharmaceutical companies are also interested in identifying SNPs associated with polygenic traits so novel therapeutic targets can be discovered. This review focuses on technologies that can be used for genotyping known SNPs as well as for the discovery of novel SNPs associated with drug response.
Export Options
About this article
Cite this article as:
Voisey Joanne and Morris Phillip Charles, SNP Technologies for Drug Discovery: A Current Review, Current Drug Discovery Technologies 2008; 5 (3) . https://dx.doi.org/10.2174/157016308785739811
DOI https://dx.doi.org/10.2174/157016308785739811 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design 1,4-Dihydropyridines as Tools for Mitochondrial Medicine Against Oxidative Stress and Associated Metabolic Disorders
Current Organic Chemistry Tumor Stem Cell Niches: A New Functional Framework for the Action of Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets Tissue Elastography: Advances in Imaging the Mechanical Properties of Tissue
Recent Patents on Electrical Engineering A Sample Selection Strategy to Boost the Statistical Power of Signature Detection in Cancer Expression Profile Studies
Anti-Cancer Agents in Medicinal Chemistry Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Development and Validation of a Highly Sensitive HPLC Method for Determination of Paclitaxel in Pharmaceutical Dosage forms and Biological Samples
Current Pharmaceutical Analysis Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model
Current Cancer Drug Targets Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases
Mini-Reviews in Medicinal Chemistry DNA Methylation Biomarkers in Serum for Gastric Cancer Screening
Mini-Reviews in Medicinal Chemistry Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry The Pharmacology of Human Appetite Expression
Current Drug Targets Curcumin Entrapped Into Lipid Nanosystems Inhibits Neuroblastoma Cancer Cell Growth and Activates Hsp70 Protein
Current Nanoscience Synthesis, Structure-Activity Relationship and Biological Activity of Acridine Derivatives as Potent MDR-Reversing Agents
Current Medicinal Chemistry Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters